Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group

Yoshimi, Ayami; Suzuki, Ritsuro; Atsuta, Yoshiko; Iida, Minako; Lu, Dao-Pei; Tong, Wei; Ghavamzadeh, Ardeshir; Alimoghaddam, Kamran; Lie, Akw; Liang, Raymond; Chan, Lee Lee; Haipeng, L; Tan, P-L; Hwang, William Yk; Tj, Chiou; Pm, Chen; Binh, Tran Van; Minh, Nguyen Nhat; Ck, Min; Hwang, Tae Ju; Kodera, Yoshihisa

doi:10.1038/bmt.2010.34

Cited by 43 publications

(39 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 More recently, the survey has included information on cellular transplants with hematopoietic stem cells for nonhematopoietic use, as well as on the use of non-hematopoietic stem and progenitor cells. 7 This coincides with the recent interest of the World Health Organization WHO (http://www.who.org) in cell and tissue transplants and further stresses the need for adequate and timely information. 8 The European Group of Blood and Marrow Transplantation (EBMT) analyses in previous years have shown an increase in the annual absolute HSCT numbers and transplant rates (number of HSCT/10 million inhabitants) of about 4-13% (median 8%) for allogeneic and of 1.5-9.5% (median 4%) for autologous HSCT, following earlier findings of the high predictability of transplant rates.…”

Section: Introductionmentioning

confidence: 99%

The EBMT activity survey: 1990–2010

Passweg

Baldomero

Gratwohl

et al. 2012

Bone Marrow Transplant

187

116

View full text Add to dashboard Cite

A total of 654 centers from 48 countries were contacted for the 2010 survey. In all, 634 centers reported a total of 33 362 hematopoietic SCT (HSCT) with 30 012 patients receiving their first transplant (12 276 allogeneic (41%) and 17 736 autologous (59%)). Main indications were leukemias: 9355 (31%; 93% allogeneic), lymphoid neoplasias specifically Non Hodgkin's lymphoma, Hodgkin's lymphoma and plasma cell disorders: 17 362 (58%; 12% allogeneic), solid tumors: 1585 (5%; 6% allogeneic) and nonmalignant disorders: 1609 (6%; 88% allogeneic). There were more unrelated donors than HLA-identical sibling donors (53% versus 41%); the proportion of peripheral blood as stem cell source was 99% for autologous and 71% for allogeneic HSCT. Cord blood was primarily used in allogeneic transplants (6% of total) with three autologous cord blood HSCT being reported. The number of transplants has increased by 19% since 2005 (allogeneic 37% and autologous 9%) and continued to increase by about 1100 HSCT per year since 2000. Patterns of increase were distinct and different. The data show the development of transplantation in Europe since 1990, with the number of patients receiving a HSCT increasing from 4200 to over 30 000 annually. The most impressive trend seen is the steady increase of unrelated donor transplantation, in parallel to the availability of unrelated donors through donor registries.

show abstract

Section: Introductionmentioning

confidence: 99%

The EBMT activity survey: 1990–2010

Passweg

Baldomero

Gratwohl

et al. 2012

Bone Marrow Transplant

187

116

View full text Add to dashboard Cite

show abstract

“…Also, latest report of HORCSCT activity suggested that up to 2010, unrelated donors had a small part in HSCT in Iran, 9 and our findings suggested that unrelated donors constitute a small proportion of donors in pediatric HSCT, as well. Another notable attribute of our donor composition was the rise in HLA-matched other related donors numbers, following separation of pediatric wing of HORCSCT in 2007.…”

Section: Discussionmentioning

confidence: 65%

“…One-year TRM probability for allogeneic indications of HSCT are as the following: 31% for IEM (95% CI: 16-46), 22% for PID (95% CI: 12-34), 19% for BMF (95% CI: 12-26), 15% for RBC abnormalities (95% CI: 12-18) and 11% for leukemias and lymphomas. [7][8][9][10][11][12][13][14][15] …”

Section: Patient Characteristicsmentioning

confidence: 99%

“…Today, HSCT is considered a well-established, effective and promising therapy for various malignant and nonmalignant medical conditions, both in children and adult patients, [4][5][6][7][8][9] and it is no longer restricted by limited sources of HSCs, donor pools or explicit need for matched family members. 7 With the availability of unrelated cord blood and safer use of HLA-matched unrelated donors, allogeneic HSCT has become available to virtually all patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hematopoietic SCT in Iranian children 1991–2012

Hamidieh

Behfar

Babaki

et al. 2015

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

This study presents the pediatric hematopoietic SCT (HSCT) activity in Iran between 1991 and 2012. Overall, 1105 fifteen-year-old or younger patients have undergone HSCT (975 allogeneic and 130 autologous). Annual HSCTs have been increasing steadily since 2007. HLA-matched siblings and other related donors were the main source of HSCs, although since 2008 a national HLA registry has been established to fill the gap for patients lacking a related donor. Inherited abnormalities of RBCs (45.88%), leukemias (27.6%) and BM failure syndromes (11.94%) constituted the majority of HSCTs during this period. Two-year overall survival and disease-free survival rates for all patients were 74.2% (95% confidence interval (CI): 71.6-77) and 66.3% (95% CI: 63.5-69.3), respectively. Leading cause of death in allogeneic group was TRM (165 deaths) and relapse caused the majority of deaths in the autologous group (39 deaths). All HSCTs from the beginning have been performed exclusively with TBI-free-conditioning regimens, which provides unique data for comparison with activities of other centers. Encouraging survival rates provide a basis for future studies on the extensive applicability of TBI-free-conditioning regimens in pediatric HSCT.

show abstract

“…The Asia-Pacific Blood and Marrow Transplantation Group (APBMT) collects data yearly on transplant activity in participating countries or regions [15,16], and has published the APBMT Activity Survey every year since 2007 [17]. The APBMT collects data for this activity survey from national registries, persons in charge of data, or receives it direct from transplant centers, depending on the country (Table 1).…”

Section: Management and Analyses Of Registry Database Of Hematopoietimentioning

confidence: 99%

Quality control and assurance in hematopoietic stem cell transplantation data registries in Japan and other countries

Kuwatsuka

2015

Int J Hematol

View full text Add to dashboard Cite

Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group

Cited by 43 publications

References 32 publications

The EBMT activity survey: 1990–2010

The EBMT activity survey: 1990–2010

Hematopoietic SCT in Iranian children 1991–2012

Quality control and assurance in hematopoietic stem cell transplantation data registries in Japan and other countries

Contact Info

Product

Resources

About